HOME >> MEDICINE >> NEWS
Should the standard guidelines for assessing prostate cancer control be changed?

The specificity and sensitivity of the ASTRO definition to predict clinical failure was 60 percent and 72 percent, respectively. Again, using three alternate definitions of clinical failure, the researchers demonstrated specificity and sensitivity results of 67 and 78 percent, 66 and 77 percent, and 64 and 74 percent.

"These alternate definitions potentially offer more accuracy in predicting who will remain free of cancer after treatment and who will truly develop metastatic disease based on a patient's post-treatment PSA levels," Horwitz said. "What's more, these results add to the current discussion in the radiation oncology community and to the body of evidence suggesting modifications to the standard ASTRO definition to predict treatment failure."

Other authors of the study include Howard D. Thames, Ph.D., department of biomathematics, University of Texas M. D. Anderson Cancer Center, Houston; Deborah A. Kuban M.D., division of radiation oncology, University of Texas M. D. Anderson Cancer Center; Larry B. Levy, M.S., department of biomathematics, University of Texas M. D. Anderson Cancer Center; Patrick A. Kupelian, M.D., department of radiation oncology, The Cleveland Clinic Foundation, Cleveland, Ohio; Alvaro A. Martinez, M.D., William Beaumont Hospital, Royal Oak, Mich.; Jeffrey M. Michalski, M.D., department of radiation oncology, Mallinckrodt Institute of Radiology, St. Louis, Mo.; Thomas M. Pisansky M.D., division of radiation oncology, Mayo Clinic, Rochester Minn.; Howard M. Sandler, M.D., department of radiation oncology, University of Michigan, Ann Arbor; William U. Shipley, M.D., department of radiation oncology, Massachusetts General Hospital, Boston; Michael J. Zelefsky, M.D., department of radiation oncology, Memorial Sloan-Kettering Cancer Center, New York City; Gerald E. Hanks, M.D., retired from the department of radiation oncology, Fox Chase Cancer Center, Philadelphia, Pa.; and Anthony L. Zietman, M.D., department of radiation
'"/>

Contact: Karen Carter Mallet
k_carter@fccc.edu
215-728-2700
Fox Chase Cancer Center
20-Oct-2003


Page: 1 2 3

Related medicine news :

1. Should medical students have earlier contact with patients?
2. Should nurses conduct breast cancer follow-up visits?
3. Should compulsory screening of immigrants be part of UK public health policy?
4. Should living liver donation be available in the NHS?
5. Should ambulance crews perform emergency breathing procedure?
6. C-reactive proteins: Should everyone be tested?
7. Should people with dementia be electronically tagged?
8. Should we help to create disabled babies?
9. Should people with diabetes sleep with the lights on?
10. Should women be screened for domestic violence?
11. Should banks be liable for pollution caused by companies that borrow from them?

Post Your Comments:
(Date:4/27/2015)... Launched by a group of ... consumers a way to connect to top local ... a patent-pending Pick Your Price matching algorithm, clients ... laser hair removal and dermal fillers on days ... in their schedules. This allows clients to take ...
(Date:4/26/2015)... has released a new blog post explaining how to find ... to find low cost auto insurance is by comparing quotes. ... in a simple and convenient way. It is no longer ... prices. All the details are now freely available to anyone ... possible to compare online car insurance quotes on a single ...
(Date:4/26/2015)... India Network Foundation, a non-profit organization in the ... the Asian Indian community in the United States and ... two decades. The India News Network Digest of 1990s ... world with the latest news items from India, the ... Forum Digest, edited and contributed by Sheela Murthy, helped ...
(Date:4/26/2015)... 2015 MidSouth Pain Treatment Center ... Southeast. MidSouth Pain Treatment Center is a comprehensive pain ... Oxford and Jackson, two ambulatory surgery centers in Germantown ... and Cordova locations. , Dr. Michael Steuer , ... medicine to help people, and when I discovered that ...
(Date:4/25/2015)... Washington, D.C. (PRWEB) April 25, 2015 ... for Bangladesh Worker Safety issues the following statement following ... 7.8 earthquake hit Kathmandu, Nepal, resulting in the deaths ... this massive earthquake were felt across Nepal, Bangladesh, India ... to offer my heartfelt condolences to the people of ...
Breaking Medicine News(10 mins):Health News:ZendyBeauty Is Pleased to Announce the Expansion and Rebranding of the Company as ZendyHealth.com 2Health News:Finding Low Cost Auto Insurance - An Online Guide Provides Tips 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 3Health News:Growing Pains for MidSouth Pain Treatment Center 2
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... , April 23, 2015 Once again, BeaconMedaes ... our commitment to patient safety. BeaconMedaes, priority ... against infectious disease. The next generation Zone ... gas sensors are now mounted in the assembly, allowing ... to open ceiling tiles potentially releasing dust spores and ...
(Date:4/23/2015)... -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its ... on Thursday, April 30, 2015, after the close of U.S.-based ... officer, will host a conference call to review the results ... (PT). The press release and a live ... a link that is posted on the home page and ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
Cached News: